The article reviews the efficacy and safety of BRAF and MEK inhibitors in treating low-grade serous ovarian cancer (LGSOC), a rare gynecological tumor with a favorable overall survival compared to other ovarian cancers but poor response to conventional chemotherapies. The RAS-MAPK pathway, particularly the BRAF and MEK components, is a key target in this context due to its frequent alterations in LGSOC. BRAF inhibitors have been approved for BRAF mutated tumors, but many patients develop resistance. Combining BRAF and MEK inhibitors has shown promising results in preclinical studies and clinical trials, delaying the onset of resistance. The article highlights the importance of understanding the mechanisms of resistance and the potential benefits of combined therapy. Ongoing trials are exploring the combination of BRAF/MEK inhibitors in LGSOC, with some showing encouraging results. The review also discusses the role of *KRAS* mutations and the need for further research to optimize treatment strategies.The article reviews the efficacy and safety of BRAF and MEK inhibitors in treating low-grade serous ovarian cancer (LGSOC), a rare gynecological tumor with a favorable overall survival compared to other ovarian cancers but poor response to conventional chemotherapies. The RAS-MAPK pathway, particularly the BRAF and MEK components, is a key target in this context due to its frequent alterations in LGSOC. BRAF inhibitors have been approved for BRAF mutated tumors, but many patients develop resistance. Combining BRAF and MEK inhibitors has shown promising results in preclinical studies and clinical trials, delaying the onset of resistance. The article highlights the importance of understanding the mechanisms of resistance and the potential benefits of combined therapy. Ongoing trials are exploring the combination of BRAF/MEK inhibitors in LGSOC, with some showing encouraging results. The review also discusses the role of *KRAS* mutations and the need for further research to optimize treatment strategies.